NEW YORK--(BUSINESS WIRE)--Aug. 2, 2006--SIGA Technologies, Inc. (NASDAQ: SIGA) today announced the receipt of $4.8 million Small Business Innovation Research (SBIR) Phase II continuation grant from the National Institutes of Health (NIH). The grant will support SIGA’s ongoing development of its lead smallpox drug candidate, SIGA-246. The company recently announced that SIGA-246 successfully completed its initial human safety clinical trial.
